Gilles Gallant
Chief Development Officer Mythic Therapeutics
Seminars
Wednesday 5th November 2025
Chair:
Download the Full Event Guide for full details
Tuesday 4th November 2025
Assessing Safety & Efficacy in the Dose Escalation of MYTX-011 Phase 1 KisMET-01 Study
11:00 am
- Unveiling efficacy data of MYTX-011 from Phase 1 KisMET-01 study
- Detailing safety and tolerability profile data from expanded patient cohorts
- Reflecting on the reasoning and rationale for MYTX-011 dose escalation
